Tongyang Life Insurance (TYANLI)
South Korea / Insurance
Active
Issuer Summary
Tongyang Life is a mid-sized Korean life insurer with more than KRW 35 trillion of assets, centred on protection-type insurance, and became part of Woori Financial Group in 2025. The current credit view, including support expectations from Woori FG, is in the mid-to-upper part of investment grade for a Korean life insurer, but a more cautious view is needed on standalone credit given the FY2025 earnings decline and the mid-range K-ICS buffer. If full ownership and group cooperation proceed as scheduled and K-ICS and insurance profit stabilise, the direction is mildly improving, but the pace of improvement is not fast. The most important point is not to treat Woori support as a legal guarantee, and to continue monitoring K-ICS, insurance profit, investment / ALM, and the ranking and principal write-down provisions of the Tier II subordinated notes.
Tongyang Life's current credit strength, including support expectations from Woori Financial Group, can be placed in the mid-to-upper part of investment grade for a Korean life insurer, but a more cautious view is needed based only on its standalone earnings and capital metrics. The direction is mildly improving if full ownership and group cooperation proceed as scheduled and if K-ICS and insurance profit stabilise, but the pace of improvement is not fast given the large FY2025 earnings decline. Under normal conditions, the probability of a rapid short-term change in level or direction is not high, but a reassessment would be needed if a decline in K-ICS, deterioration in investment-asset valuations, changes in Woori's support policy, integration burden, and activation risk of subordinated-debt provisions occur together.
This view is supported by Woori FG's acquisition of Tongyang Life and ABL Life and the planned full ownership in August 2026. Woori's support capacity, banking franchise, capital-market access and strategic importance within the group clearly strengthen the company's standalone credit. However, Woori support is not a legal guarantee, and Tongyang Life's own FY2025 earnings decline, mid-range K-ICS buffer, investment and ALM sensitivity, and the ranking and principal write-down provisions of the Tier II subordinated notes remain.
Monitoring from here should focus first on whether the July 2026 shareholder meeting and August share exchange proceed as scheduled, second on whether K-ICS stabilises around 180%, and third on whether insurance profit, net profit and CSM recover from the weakness in FY2025. In addition, overseas securities, OCI, hedging, duration gap, the refinancing environment for subordinated debt, and Woori's capital policy should be reviewed. If K-ICS declines toward 150%, insurance profit remains depressed, Woori support expectations weaken, or optional-redemption / principal write-down risk on the Tier II notes becomes more salient, the credit view should be reconsidered in a negative direction.
Issuer Reports
Current public reports for this issuer.